ORAMED PHARMACEUTICALS INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/19f86b2d-ef26-4035-8b20-b88093b704eb/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $2.0M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-034835 |
| FY 2023 | $1.3M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-020485 |
| FY 2022 | $2.7M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-017837 |
| FY 2021 | $2.7M | 2020-09-01 – 2021-08-31 | evidence 0001213900-21-062009 |
| FY 2020 | $2.7M | 2019-09-01 – 2020-08-31 | evidence 0001213900-20-038924 |
| FY 2019 | $2.7M | 2018-09-01 – 2019-08-31 | evidence 0001213900-19-024940 |
| FY 2018 | $2.4M | 2017-09-01 – 2018-08-31 | evidence 0001213900-18-016666 |
| FY 2017 | $2.5M | 2016-09-01 – 2017-08-31 | evidence 0001213900-17-012754 |
| FY 2016 | $641.0k | 2015-09-01 – 2016-08-31 | evidence 0001213900-16-018954 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ORAMED PHARMACEUTICALS INC. — all facts · Net Income · Operating Income